Ignite Creation Date:
2024-05-06 @ 6:52 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05817240
Status:
COMPLETED
Last Update Posted:
2023-12-15
First Post:
2023-04-05
Brief Title:
A Drug-Drug Interaction Study of ENV-101 Taladegib on Nintedanib Pharmacokinetics in Healthy Subjects
Sponsor:
Endeavor Biomedicines Inc
Organization:
Endeavor Biomedicines Inc
Study Overview
Official Title:
A Phase 1 Single-Center Fixed Sequence Drug-Drug Interaction Study of ENV-101 Taladegib on Nintedanib Pharmacokinetics in Healthy Subjects
Status:
COMPLETED
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to learn about the potential effect of ENV-101 taladegib on the pharmacokinetics of nintedanib an approved treatment for idiopathic pulmonary fibrosis when the two compounds are dosed together in healthy subjects Participants in this study will receive ENV-101 andor nintedanib on various days throughout a 10-day period during which they will reside at the clinical trial site
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None